Filing Analysis
BioAtla, Inc. has received a final decision from the Nasdaq Listing Council affirming the delisting of its common stock from Nasdaq. Trading is expected to be suspended on Nasdaq on August 31, 2026, with the stock likely moving to the OTC Markets.
🚩 Red Flags
- Confirmed delisting from Nasdaq.
- Failure to meet minimum bid price ($1.00) and stockholders' equity ($2.5M) requirements.
- Going concern language included in forward-looking statements regarding the need for additional funding.
- Potential material adverse effect on trading price and volume due to move to OTC Markets.
📋 Key Facts
- Nasdaq Listing Council affirmed the prior delisting determination on August 26, 2026.
- Delisting is due to non-compliance with the $1.00 bid price requirement and failure to meet the $2.5 million stockholders' equity requirement.
- Trading on Nasdaq is expected to be suspended at the opening of business on August 31, 2026.
- The company expects to be eligible for quotation on the OTC Markets system under the symbol BCAB.
- The company is currently undergoing a formal process to explore strategic options to maximize shareholder value, initiated in March 2026.
BioAtla, Inc. held its Annual Meeting of Stockholders on July 16, 2026. The meeting resulted in the election of two Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held via live audio webcast on July 16, 2026.
- Quorum reached with 906,983 shares (approx. 55% of total outstanding shares) present in person or by proxy.
- Jay M. Short, Ph.D. and Edward Williams were elected to the Board of Directors for three-year terms.
- Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Non-binding advisory vote on executive compensation was approved.
BioAtla, Inc. has filed a certificate of merger to effect a 1-for-50 reverse stock split, effective April 6, 2026. The transaction involves merging with a wholly-owned subsidiary to consolidate every 50 existing shares into one single share of common stock.
🚩 Red Flags
- Large 1-for-50 reverse stock split ratio, often indicative of a need to regain compliance with minimum bid price requirements for exchange listing.
- Reverse splits are frequently viewed negatively by the market as they do not change underlying fundamentals but reduce share count to inflate price.
📋 Key Facts
- Certificate of Merger filed with the Secretary of State of Delaware on April 2, 2026.
- The merger is between BioAtla, Inc. and its wholly-owned subsidiary, BA Merger Sub, Inc.
- Effective Time is set for April 6, 2026, at 12:01 a.m. Eastern Time.
- Conversion ratio: Every fifty (50) shares of common stock will be converted into one (1) share of common stock.
- The action follows a previously announced Agreement and Plan of Merger dated January 30, 2026.
BioAtla, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided an updated corporate presentation for upcoming investor and strategic partner meetings.
📋 Key Facts
- Financial results for Q4 and FY 2025 were released on March 31, 2026.
- The company updated its corporate presentation (Exhibit 99.2) for use with investment banks, industry analysts, and potential strategic partners.
- The report was furnished under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD Disclosure).
- The filing was signed by Christian Vasquez, Chief Financial Officer.
BioAtla stockholders approved a massive 1-for-50 reverse stock split to be implemented via an internal merger. Concurrently, the company established a retention bonus program for its CEO, CFO, and CMO that is strictly tied to achieving 'capital raising milestones' by August 2026, following a year where no bonuses were paid due to missed financial targets.
🚩 Red Flags
- Extremely high 1-for-50 reverse split ratio often indicates a stock price well below listing requirements.
- Executive compensation is explicitly tied to 'capital raising,' suggesting an urgent need for liquidity.
- Failure to meet any financial milestones or business objectives in 2025.
- Company-wide salary freeze and lack of 2025 bonuses indicate significant financial distress.
- The retention bonus payouts are subject to a sliding scale that allows for zero payout if milestones are missed by more than 20%.
📋 Key Facts
- Stockholders approved a 1-for-50 reverse stock split (Share Consolidation) on March 23, 2026.
- Retention bonuses for CEO Jay M. Short, CFO Christian Vasquez, and CMO Eric Sievers are contingent on 'financial and capital raising milestones' by May 31 and August 31, 2026.
- CEO Jay M. Short's target retention bonus is $449,712 (60% of base salary).
- CFO and CMO target retention bonuses total 50% of their respective base salaries.
- No bonuses were earned by any employees in 2025 as financial milestones were not met.
- There will be no salary increases for any Company employees in 2026.
- The reverse split will be implemented as soon as possible following Nasdaq notice periods.
BioAtla, Inc. has announced a massive 70% workforce reduction and initiated a formal process to explore strategic alternatives, including a potential sale of the company. The company is currently facing delisting from Nasdaq due to non-compliance with bid price and stockholders' equity requirements, and is implementing a 1-for-50 reverse stock split.
🚩 Red Flags
- Massive 70% workforce reduction indicates severe operational distress.
- Extremely low cash position ($7.1M) for a clinical-stage biotech company.
- Nasdaq delisting notice and ongoing appeal process.
- 1-for-50 reverse stock split is a highly dilutive/distress signal.
- Failure of a critical $40 million financing transaction to close as planned.
- CFO departure during a period of financial crisis.
📋 Key Facts
- Workforce reduction of approximately 70% committed on February 24, 2026.
- Cash and cash equivalents estimated at only $7.1 million as of December 31, 2025.
- Nasdaq issued a Delist Determination on February 6, 2026, for failure to meet the $1.00 bid price and $2.5 million stockholders' equity requirements.
- A 1-for-50 reverse stock split is being implemented via a merger agreement with a wholly owned subsidiary.
- CFO Richard Waldron is departing effective March 2, 2026, replaced by CAO Chris Vasquez.
- A previously announced $40 million SPV transaction with Inversagen AI is being revised as the lead investor (AIRC) has not completed its investment.
BioAtla, Inc. has received notice that the Nasdaq Listing and Hearing Review Council will review a decision to suspend trading and delist the company's securities. While the delisting action is currently stayed pending the review, the company faces significant compliance issues regarding minimum bid price and stockholders' equity requirements.
🚩 Red Flags
- Delisting notice/suspension of trading
- Non-compliance with $1.00 minimum bid price requirement
- Failure to meet stockholders' equity requirements ($2.5M)
- Going concern risk mentioned in forward-looking statements (need for additional funding to continue development)
📋 Key Facts
- Nasdaq's February 6, 2026, decision to suspend trading was effective as of market open on February 10, 2026.
- The company is non-compliant with the $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- The company failed to meet the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1).
- The Nasdaq Listing Council has stayed the suspension and delisting action pending a review process that may take several weeks to months.
- The company is disputing Nasdaq's decision, alleging 'irreparable harm' due to Nasdaq's handling of compliance status and policy changes regarding super-voting stock.
BioAtla, Inc. has received a delisting determination from Nasdaq due to non-compliance with the $1.00 bid price requirement and failure to meet stockholders' equity requirements. Trading is scheduled to be suspended on February 10, 2026, unless an immediate stay is granted by the Listing Council.
🚩 Red Flags
- Imminent delisting/suspension of trading on Nasdaq.
- Non-compliance with minimum bid price ($1.00).
- Failure to meet stockholders' equity requirement ($2.5 million).
- Going concern risk explicitly mentioned in forward-looking statements regarding the need for additional funding.
- Potential loss of liquidity if shares move to OTC markets.
📋 Key Facts
- Nasdaq Hearings Panel determined delisting based on violation of Nasdaq Listing Rule 5550(a)(2) ($1.00 bid price) and Rule 5550(b)(1) (stockholders' equity).
- Trading suspension is set to take effect at the open of business on February 10, 2026.
- The Company has submitted a 'Call for Review Request' to the Nasdaq Listing Council to seek an immediate stay of the suspension.
- $1.25 million in principal remains outstanding under Pre-Paid Advance Agreements (PPAs) with Yorkville and Anson Investments.
- A Standby Equity Purchase Agreement (SEPA) allows for up to $15.0 million in share sales, but these are precluded if the stock is suspended from Nasdaq.
BioAtla, Inc. is implementing a 50-for-1 reverse stock split via a merger with a wholly owned subsidiary to circumvent unannounced Nasdaq regulatory changes regarding super-voting shares. This follows an unsuccessful attempt to approve a standard reverse split using super-voting preferred stock.
🚩 Red Flags
- Reverse stock split implementation (highly dilutive/structural change).
- Regulatory conflict with Nasdaq regarding 'Voting Rights Rule' and super-voting shares.
- Use of complex financial engineering (super-voting preferred stock) to bypass retail shareholder voting thresholds.
- Potential delisting risk if the merger structure is deemed non-compliant by Nasdaq.
📋 Key Facts
- The company will execute a 50-for-1 reverse stock split through a merger with a wholly owned subsidiary (Merger Sub).
- A previous attempt to pass a reverse split via 'Series A Junior Preferred Stock' (super-voting shares) was technically successful but blocked by Nasdaq policy changes.
- Nasdaq informed the company that using super-voting preferred stock to approve reverse splits is no longer permitted, despite previous guidance.
- The Board redeemed the Series A Junior Preferred Stock for $0.01 on January 30, 2026.
- A merger agreement was entered into on January 30, 2026, to facilitate the share reduction; a special meeting is set for early February 2026.
- The company received confirmation of a $5 million investment from Inversagen AI/AIRC related to its SPV subsidiary.
BioAtla, Inc. has issued a 'Super-Voting Share' to its CEO/Chairman to bypass stockholder opposition and force through a proposed reverse stock split. This follows a failed attempt to secure the required two-thirds majority vote for the split at a recent special meeting.
🚩 Red Flags
- Issuance of Super-Voting shares to an insider (CEO/Chairman) to override shareholder voting outcomes.
- Failed attempt to pass a reverse stock split indicates significant shareholder opposition or lack of quorum/support for compliance measures.
- The company is actively seeking a reverse split, which is often used to regain Nasdaq compliance after falling below minimum bid price requirements.
📋 Key Facts
- On January 9, 2026, the Board authorized the issuance of one share of Series A Junior Preferred Stock ('Super-Voting Share') to CEO Jay M. Short for $0.01.
- The Super-Voting Share is designed to cast votes equal to all outstanding Common Stock specifically regarding a reverse stock split proposal.
- A previous special meeting held on January 12, 2026 (reconvened), failed to reach the required two-thirds (2/3) voting threshold for the Reverse Stock Split Proposal despite having over 70% 'FOR' votes from those present.
- The proposed reverse stock split range is between 1-for-5 and 1-for-20.
- A reconvened special meeting is scheduled for January 26, 2026.
BioAtla, Inc. entered into a material investment agreement with Inversagen AI, LLC to sell equity in a newly formed subsidiary (SPV) for up to $40 million. The transaction involves significant related-party involvement as the CEO and his spouse serve as managers of the investing entity.
🚩 Red Flags
- Related-party transaction: The CEO (Dr. Jay Short) and his spouse are managers of Inversagen AI, LLC, the entity investing $40M.
- Complex/Indirect structure: Use of a Special Purpose Vehicle (SPV) to facilitate the sale of IP rights rather than direct equity in BioAtla itself.
- Going concern risk mentioned in forward-looking statements regarding the need for additional funding.
📋 Key Facts
- BioAtla entered into an Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. (AIRC) on December 30, 2025.
- The company will sell common units of its wholly-owned subsidiary, BA 3021 SPV LLC, to Inversagen AI in two closings.
- Total potential investment is $40 million for a 35% ownership stake in the SPV.
- First closing expected before January 30, 2026: $5 million for 4.375% of SPV units.
- Second closing (expected by March 31, 2025 [sic - likely typo in filing for 2026]) contingent on a $35 million financing to purchase an additional 30.625% stake.
- Proceeds are earmarked for general operating expenses and Phase 3 clinical trials of 'Oz-V' (ozuriftamab vedotin) for oropharyngeal squamous cell carcinoma.
- The SPV will hold an exclusive, worldwide, perpetual license to BioAtla’s IP in Oz-V for non-oncology senescent cell elimination therapy.
BioAtla, Inc. held a special meeting of stockholders where shareholders failed to approve a proposed reverse stock split (ranging from 1-for-5 to 1-for-20). The company has adjourned the meeting until January 12, 2026, to solicit additional proxies for the proposal.
🚩 Red Flags
- Failed vote on a reverse stock split (often used to maintain Nasdaq listing compliance).
- Approval of Proposal No. 1 allows for issuance of common stock in excess of previously established caps, indicating potential significant dilution.
- The need to adjourn the meeting specifically to 'solicit additional proxies' suggests management is struggling to secure shareholder support for critical structural changes.
📋 Key Facts
- Special Meeting held on December 30, 2025.
- Proposal No. 2 (Reverse Stock Split) failed to receive sufficient votes and was not approved.
- The proposed reverse split range was 1-for-5 to 1-for-20.
- Proposal No. 1 (Issuance of stock in excess of Exchange Cap via Yorkville/Anson agreements) was approved with 19,772,270 votes in favor.
- The meeting has been adjourned to January 12, 2026, specifically to solicit more proxies for the reverse split proposal.
BioAtla, Inc. entered into two significant financing agreements: a $7.5 million Pre-Paid Advance Agreement (PPA) and a $15.0 million Standby Equity Purchase Agreement (SEPA) with Yorkville/related parties. These agreements involve highly dilutive equity structures, including variable price conversion mechanisms and potential cash repayment obligations triggered by stock price declines.
🚩 Red Flags
- Highly dilutive financing: Both agreements utilize variable price mechanisms that favor the investor and can lead to significant share issuance at low prices.
- Death Spiral-like features: The PPA includes a 'Floor Price' mechanism where if the stock drops, the company may be forced into cash repayments of 18% plus premiums.
- Immediate liquidity need: The structure suggests an urgent requirement for capital through high-cost equity financing.
- Significant potential dilution: Combined total of $22.5M in potential new shares/obligations against a micro-cap market cap.
📋 Key Facts
- Entered into a $7.5M Pre-Paid Advance Agreement (PPA) on November 20, 2025.
- The PPA is subject to a 95% discount on the face amount for gross proceeds of ~$7.13 million.
- Investors can convert the advance into shares at the lower of 115% of VWAP or $1.39 (Fixed Price), with a floor price set at 20% of the closing price prior to closing.
- Entered into a $15.0M Standby Equity Purchase Agreement (SEPA) with Yorkville for up to 36 months.
- The SEPA allows investors to purchase shares at 97% of the lowest daily VWAP over three consecutive days.
- Total potential dilution is capped by an 'Exchange Cap' at 19.99% of outstanding shares unless stockholder approval is obtained.
- Default triggers include failure to make timely SEC reports or trading suspensions.
BioAtla, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2025, and provided clinical program updates.
📋 Key Facts
- Report date: November 13, 2025
- Reporting period: Quarter ended September 30, 2025
- Content includes financial results and clinical program updates via Exhibit 99.1
- The information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
BioAtla, Inc. has received a decision from the Nasdaq Hearing Panel granting continued listing on conditional terms. The company must transfer to the Nasdaq Capital Market by September 26, 2025, and meet specific equity and bid price requirements by late 2025 and early 2026.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq rules (Minimum Bid Price and Minimum Stockholders' Equity).
- Mandatory transfer from Nasdaq Global Market to Nasdaq Capital Market.
- Explicit mention of risks that 'raise substantial doubt about the Company's ability to continue as a going concern'.
- Need for additional funding to continue development of CAB technology platform.
📋 Key Facts
- Nasdaq Hearing Panel granted a request for continued listing on conditional terms.
- Company must file an application to transfer to The Nasdaq Capital Market on or before September 26, 2025 (Application submitted Sept 18, 2025).
- Must demonstrate compliance with Minimum Stockholders’ Equity Requirement by December 31, 2025.
- Must demonstrate compliance with Minimum Bid Price Requirement by February 2, 2026.
- The company previously received a delist determination on August 6, 2025.
BioAtla, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025, and provided updates regarding its clinical programs.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Quarter ended June 30, 2025
- Content includes financial results and clinical program updates via Exhibit 99.1
- The information is furnished under Item 2.02 and not filed for purposes of Section 18 liability.
BioAtla, Inc. announced the approval of its 2025 Corporate Bonus Plan for executive officers and reported results from its Annual Meeting of Stockholders held on June 18, 2025.
🚩 Red Flags
- High weighting (50%) of executive bonuses tied specifically to 'financing objectives', which may indicate a focus on capital raising over operational milestones.
📋 Key Facts
- The 2025 Corporate Bonus Plan includes clinical development milestones (25%), financing objectives (50%), financial/people objectives (20%), and brand awareness (5%).
- CEO Jay Short has a target bonus of 60% of base salary; CFO Richard Waldron and CMO Eric Sievers have targets of 40%.
- Annual Meeting held on June 18, 2025, with approximately 52% of total outstanding shares represented (30,358,471 shares).
- Stockholders ratified the appointment of Ernst & Young LLP as independent auditors for fiscal year 2025.
- Three Class II directors (Mary Ann Gray, Susan Moran, and Lawrence Steinman) were elected to three-year terms.
BioAtla, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market. As of March 31, 2025, the company reported only $547,000 in stockholders' equity, significantly below the required $10,000,000.
🚩 Red Flags
- Delisting notice from Nasdaq (Item 3.01).
- Extreme deficiency in stockholders' equity ($547k vs $10M requirement).
- Forward-looking statements explicitly mention 'factors that raise substantial doubt about the Company's ability to continue as a going concern'.
- Need for additional funding to continue development of CAB technology platform.
📋 Key Facts
- Received written notice from Nasdaq on May 12, 2025.
- Stockholders' equity was $547,000 as of March 31, 2025.
- Failed to meet the $10,000,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5450(b)(1)(A).
- Company did not meet alternative compliance standards regarding market value of listed securities or total assets/revenue.
- Deadline to submit a Compliance Plan is June 26, 2025.
- If the plan is accepted, Nasdaq may grant a 180-day extension.
BioAtla, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025, and provided updates regarding its clinical programs.
📋 Key Facts
- Report date: May 6, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and clinical program updates.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
BioAtla, Inc. announced a significant workforce reduction of approximately 30% to streamline operating costs and prioritize development programs. The company also released its Q4 and fiscal year 2024 financial results.
🚩 Red Flags
- Significant workforce reduction (30%) indicating cost-cutting measures.
- Explicit mention of 'factors that raise substantial doubt about the Company’s ability to continue as a going concern' in forward-looking statements.
- Need for additional funding mentioned as a risk factor to continue development.
📋 Key Facts
- Workforce reduction of approximately 30% committed on March 21, 2025.
- Estimated cash payments for severance and benefits: $0.5 million to $0.6 million.
- Majority of restructuring costs expected in Q2 2025.
- Financial results for the fourth quarter and fiscal year ended December 31, 2024 were released on March 27, 2025.
BioAtla, Inc. announced the approval of 2024 cash bonuses and new equity awards (RSUs) for its top three executive officers: the CEO, CFO, and CMO.
🚩 Red Flags
- Executives only achieved 62.5% of their target bonus, suggesting missed performance metrics or conservative milestone setting.
📋 Key Facts
- Approved $120,160 cash bonus for CFO Richard Waldron (62.5% of target).
- Approved $127,555 cash bonus for CMO Eric Sievers (62.5% of target).
- Approved $275,558 cash bonus for CEO Jay Short (62.5% of target).
- Bonuses were tied to achievement of clinical development, R&D milestones, and business objectives in 2024.
- Granted 100,000 RSUs to Richard Waldron and 175,000 RSUs to Eric Sievers effective March 11, 2025.
- Granted 431,000 RSUs to Jay Short effective March 12, 2025.
- RSU vesting schedules include a 25% cliff on the one-year anniversary followed by quarterly installments.
BioAtla, Inc. received a notice from Nasdaq stating it is non-compliant with the minimum $1.00 bid price requirement (Rule 5550(a)(2)). The company has until August 5, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq Rule 5550(a)(2))
- Potential for stock price volatility associated with delisting risk
- Risk of transfer from Nasdaq Global Market to Nasdaq Capital Market if compliance is not met
📋 Key Facts
- Received Nasdaq notice on February 6, 2025.
- Non-compliance due to failure to maintain a minimum closing bid price of $1.00 for the last 30 consecutive business days.
- The company has a primary compliance period of 180 days ending August 5, 2025.
- A second 180-day extension is possible if the company transfers to Nasdaq Capital Market and meets other listing standards.
BioAtla, Inc. entered into a securities purchase agreement for a registered direct offering of 9,679,158 shares of common stock and an equal number of warrants at a combined price of $0.9520 per unit.
🚩 Red Flags
- Significant dilution: Issuance of nearly 9.7 million shares plus warrants representing a large percentage of float.
- Warrant overhang: Warrants are exercisable at $1.19, which is higher than the current offering price ($0.952), potentially creating future dilution.
- Lock-up/Standstill: Officers and directors are subject to a 75-day lock-up; company has a 180-day standstill on variable rate transactions.
📋 Key Facts
- Aggregate gross proceeds expected to be approximately $9.2 million before fees.
- Offering includes 9,679,158 shares of common stock and 9,679,158 warrants.
- Warrants are exercisable six months after issuance at an exercise price of $1.19 per share.
- The offering is being conducted via a registered direct offering under an existing S-3 shelf registration.
- Proceeds are earmarked for R&D (BA3182 and mecbotamab vedotin programs) and working capital.
BioAtla, Inc. filed an 8-K to update its corporate presentation under Regulation FD disclosure. This is a routine filing used to provide updated investor information and does not contain material financial changes or structural shifts.
📋 Key Facts
- The company updated its corporate presentation (Exhibit 99.1).
- The filing was made pursuant to Item 7.01 Regulation FD Disclosure.
- The information is furnished but not 'filed' for purposes of Section 18 liability.
BioAtla, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided updates on its clinical programs.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- Content includes financial results and clinical program updates via Exhibit 99.1
- Filed under Item 2.02 (Results of Operations and Financial Condition)
BioAtla, Inc. entered into an exclusive worldwide license agreement with Context Therapeutics Inc. for its Nectin-4 x CD3 bispecific antibody (BA3362/CT-202). The deal includes up to $133.5 million in aggregate payments and royalties.
🚩 Red Flags
- Context Therapeutics has the right to terminate the agreement 'at will' upon advance written notice.
- BioAtla is subject to non-compete restrictions regarding Nectin-4 directed bispecific or multi-specific antibodies.
📋 Key Facts
- License Agreement dated September 23, 2024, with Context Therapeutics Inc.
- Assets include BA3362 (renamed CT-202), a Nectin-4 x CD3 T cell engaging bispecific antibody.
- Total potential consideration of $133.5 million: $15.0 million in upfront/near-term milestones and $118.5 million in development/commercial milestones.
- BioAtla to receive tiered mid-single digit to low double-digit royalties on future net sales.
- Himalaya Therapeutics SEZC consented via a Global Transaction Agreement, receiving a mid-teens percentage of upfront/development milestones and specific royalty percentages for China/HK/Macao/Taiwan territories.
BioAtla, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided updates on its clinical programs.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and clinical program updates.
BioAtla, Inc. held its Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the election of a new director and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held via live audio webcast on June 13, 2024.
- Quorum reached with 34,513,932 shares (approx. 71.75% of total outstanding shares) present in person or by proxy.
- Sylvia McBrinn was elected to the Board of Directors for a three-year term (received 15,280,856 votes 'For').
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Non-binding advisory vote on executive compensation was approved by stockholders.
BioAtla, Inc. announced the settlement and closure of a shareholder class action lawsuit regarding its corporate bylaws. The company agreed to pay $350,000 in legal fees to settle claims that certain bylaw amendments were overly restrictive to dissident directors.
🚩 Red Flags
- Litigation involving allegations of breach of fiduciary duty by directors.
📋 Key Facts
- The lawsuit was filed on February 6, 2024, in the Delaware Court of Chancery.
- Plaintiff Upendar Golla alleged breach of fiduciary duty regarding amended bylaws adopted on January 5, 2024.
- The company modified the challenged bylaw provisions on April 22, 2024.
- BioAtla agreed to pay $350,000 in attorneys' fees and expenses to settle all claims.
- The Court entered an order closing the action on May 15, 2024.
BioAtla, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024, and provided updates regarding its clinical programs.
📋 Key Facts
- Report date: May 14, 2024
- Reporting period: Quarter ended March 31, 2024
- Content includes financial results and clinical program updates via Exhibit 99.1
- Filed under Item 2.02 (Results of Operations and Financial Condition)
BioAtla, Inc. has amended and restated its Bylaws, effective April 22, 2024. The changes primarily focus on modifying advance notice requirements for stockholder-submitted nominations and business proposals.
📋 Key Facts
- Board approved amendment and restatement of the Company's Bylaws on April 22, 2024.
- Changes include relaxing disclosure requirements regarding 'Acting in Concert' entities for proposing persons.
- Stockholders may now cure deficiencies or inaccuracies in Timely Notices up to the deadline.
- Removed requirement for stockholders/nominees to respond to Company requests within seven business days.
- Removed requirement for proposed nominees to submit to interviews with the Company.
BioAtla, Inc. filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: March 26, 2024.
- The filing includes a press release (Exhibit 99.1) containing the financial results.
BioAtla, Inc. announced the approval of 2023 cash bonuses and equity awards for its named executive officers based on clinical and business milestones. The company also established a new 2024 Corporate Bonus Plan with performance metrics tied to clinical, strategic, financing, and R&D goals.
🚩 Red Flags
- High executive compensation relative to typical micro-cap cash burn profiles, though tied to specific milestones.
📋 Key Facts
- Approved 2023 cash bonuses for CEO Jay Short ($419,491), CFO Richard Waldron ($184,718), CMO Eric Sievers ($184,338), and CAO Christian Vasquez ($115,800).
- Bonuses represent 98% of target amounts based on achievement of clinical/R&D milestones.
- Granted time-based Restricted Stock Units (RSUs) to the four named executives effective Feb 15/16, 2024.
- Established 2024 Corporate Bonus Plan with weighted goals: Clinical (30%), Strategic Partnerships (20%), Financing (20%), R&D (10%), Financial/People (10%), and Brand Awareness (10%).
- Christian Vasquez promoted to Chief Accounting Officer effective Jan 1, 2024.
BioAtla, Inc. announced that a class action lawsuit has been filed against the company and its Board in Delaware Chancery Court regarding the validity of certain advance notice bylaws. In response to the litigation, the Board has decided to temporarily waive several disclosure and procedural requirements for stockholder proposals/nominations at the upcoming 2024 Annual Meeting.
🚩 Red Flags
- Putative class action lawsuit targeting the Board of Directors.
- Allegations of breach of fiduciary duty (care, loyalty, and good faith).
- Legal uncertainty regarding corporate governance bylaws which could impact shareholder activism or board composition.
📋 Key Facts
- Upendar Golla filed a putative class action lawsuit (C.A. No. 2024-0100-JTL) in Delaware Court of Chancery on February 6, 2024.
- The lawsuit alleges that certain 'Challenged Provisions' in the company's advance notice bylaws are invalid and unenforceable.
- The Board is accused of breaching fiduciary duties of care, loyalty, and good faith by adopting these provisions.
- The Board will not enforce specific disclosure requirements regarding associated persons, derivative positions, or material terms of agreements for the 2024 Annual Meeting.
- The Board will waive requirements for nominees to provide names/addresses of supporting stockholders and requirements for interviews with the Board.
BioAtla, Inc. filed an 8-K to update its corporate presentation in preparation for investor meetings and the 42nd Annual J.P. Morgan Healthcare Conference.
📋 Key Facts
- The company updated its Corporate Presentation on January 9, 2024.
- The presentation is intended for use with investors, investment banks, and analysts.
- Specifically mentions upcoming participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.
BioAtla, Inc. announced the adoption of Amended and Restated Bylaws effective January 5, 2024. The changes primarily align company governance with recent amendments to the Delaware General Corporation Law (DGCL) and SEC Universal Proxy Rules.
📋 Key Facts
- Board approved and adopted Amended and Restated Bylaws on January 5, 2024.
- Bylaws updated to conform to recent amendments to the Delaware General Corporation Law (DGCL).
- New provisions added regarding 'Universal Proxy Rules' under Rule 14a-19 of the Securities Exchange Act.
- Added an emergency bylaw provision allowing directors/officers authority during situations preventing a quorum.
- Revised advance notice procedures, including requirements for stockholder nominations and proxy solicitation disclosures.